A/Prof Mary Bebawy has a BSc (Hons) UNSW, PhD (Pharmacy) USYD. She specialises in the role and regulation of the xenobiotic cascade in drug disposition and in cancer multidrug resistance (MDR).
In addition to 16 years in academic research and teaching positions, she has spent 2 years in industry as a Post doctoral Preclinical Drug Development Scientist with Johnson and Johnson, Research, Sydney (2002-04) and one year as Associate Dean (Undergraduate) at The Pharmacy Faculty, USyd (2004-05), a position for which she was nominated. She has consulted to academia and industry on assay development, drug discovery and cancer resistance mechanisms. She has recently been appointed (by invitation) to the position of Associate Professor at the University of Technology, Sydney with the Graduate School of Pharmacy. Associate Professor Mary Bebawy is also the inaugural Responsible Academic Officer for Research and Innovation for the Graduate School of Health at UTS. Her responsibilities also include the Research and Innovation portfolio for the Graduate School of Health.
Abstracts this author is presenting: